DHL Group has announced an investment of two billion euros over the next five years to enhance its logistical capabilities in the life sciences and health care sector.
An official statement says that investment supports the group 2030, and enhances the DHL commitment to the help of health care customers to grow, innovate and serve patients more effectively around the world. “With the allocation of 50 percent of the investment allocated to the Americas, 25 percent for the Pacific Asia and 25 percent to the Europe, the Middle East and Africa region, DHL expands its global scope to provide integrated logistical solutions, faster, more reliable and centered around the patient where health care companies work.”
An important part of the investment will be allocated to create new pharmacy centers accredited by GPD for multi -heat shipping corridors, expanding the capacity of the cold chain in the current facilities, providing new controlling new compounds, and enhancing negative and effective packaging solutions to ensure sustainable connection.
“With the growth of demand in critical areas such as clinical trials, biomedics, cell treatments and genes, DHL also invests in high -quality and specialized cooling infrastructure to accommodate very low and low ranges.
“Through its new HELTH LOGISTICS brand, the group works to integrate life sciences and healthcare experiences in one unified umbrella. This creates a smooth and final experience for customers, simplifying the management of complex supply chains, confidence -related lines, and light -quality lightness service.
The statement added that the DHL group expands its scope to suit the rapidly developed needs of industry, healthcare users and patients alike, with an additional 5 billion euros of expected additional revenues by 2030, DHL GROUP expands its operations to suit the advanced needs of the industry and final users-healthcare professionals and patients alike. “Similar to the purpose of DHL Group, which is to connect people and improve lives, our strategic investment in life sciences and health care is driven by our customers’ mission: providing basic products and saving life to people in need, “says Oscar de Book, Executive Director of the DHL supply chain. “We are building high-quality, integrated and reliable logistical solutions like the products that our customers create-ensuring that patients everywhere get the appropriate treatment, at the right time, with complete confidence.”
“Similar to the purpose of DHL Group, which is to connect people and improve lives, our strategic investment in life sciences and health care is driven by our customers’ mission: providing basic products and saving life to people in need, “says Oscar de Book, Executive Director of the DHL supply chain.
“We are building high-quality, integrated and reliable logistical solutions like the products that our customers create-ensuring that patients everywhere get the appropriate treatment, at the right time, with complete confidence.” DHL Group currently runs nearly 600 sites, centers and warehouses across nearly 130 countries dedicated to life sciences and logistics services for health care, which includes a total of more than 2.5 million square meters of the warehouse area that is controlled in the temperature. The DHL group has recently obtained Cryopdp, a leading company in clinical trials that focus on clinical trials, biological treatments, cells and genes to increase the enhancement of its capabilities in the sector.
